Kymab has appointed Dr Sonia Quaratino as its chief medical officer – a newly created role that will see her manage clinical development of the group’s expanding therapeutic antibody portfolio.
She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
Dr Quaratino said: “Kymab’s emerging human antibody pipeline provides great potential to improve patient treatment options in our four main therapeutics areas of focus.”
She previous served Novartis as its global clinical programme leader, transitional clinical oncology, with responsibility for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology.
Prior to her time at Novartis, Quaratino worked for Merck Serono, where she was responsible for the clinical development of various immunomodulators.
Dr David Chiswell, CEO of Kymab, said: “I am delighted to welcome Sonia to Kymab. With her track demonstrated track record in clinical development and medical affairs, Sonia is a superb addition to Kymab’s management team as we prepare for our first clinical trials.
“Sonia’s deep understanding of the global environment in clinical research compliment those of Dr Arndt Schottelius, our new executive VP of R&D. These two key appointments add high calibre of depth and provide further validation to our burgeoning and advancing R&D pipeline.”